The Health Corporation-Rambam (Rambam) - Israel
Rambam Health Care Campus (Rambam) is a 1,000-bed academic hospital serving more than two million people in northern Israel. Rambam is the tertiary referral center for twelve district hospitals, the Israel Defence Forces Northern Command, the US Navy Sixth Fleet and the UN Peacekeeping Forces posted in the region. It is the exclusive provider in northern Israel of comprehensive treatment in such disciplines as neurosurgery, oncology, and major trauma. The Health Corporation – Rambam is a non-profit authorized organization managing Rambam's research activity. The Unit of Infectious Diseases at Rambam comprises of 7 senior physicians and 2 residents. The Microbiology Laboratory serves as a national reference center for molecular microbiology. Rambam is affiliated to The Technion - Israel Institute of Technology, a world-known center of research excellence. The Ruth and Bruce Rappaport Faculty of Medicine manages one the five medical schools in Israel.
Rambam is WP-leader for WP1 ((Multicenter, open-label, randomized clinical trial to compare colistin alone vs. colistin plus imipenem for severe infections caused by carbapenem-resistant bacteria) and will coordinate the clinical trial. Rambam will design the protocol for the trial in collaboration with all participants and coordinate the set-up for the trial in the individual trial sites, including the local requirements of the ethics committees. As there is considerable confusion with regard to colistin dosing and units, Rambam will ensure that the same preparation is used in all sites. Rambam will actively monitor the trial in the different clinical sites, to ensure that enrolment proceeds as planned and that all trial procedures are adequately followed. If one of the sites cannot recruit the planned number of patients, Rambam will be responsible to recruit the alternative site as specified in the proposal. Rambam will ensure uniform and full data collection at all the protocol-pre-specified time points and merge the data into a uniform database. Rambam will analyze the trial results and will e responsible for publication and dissemination of the results
Mical Paul and the Unit of Infectious Diseases at Rambam will lead the WP1 clinical trial. Currently there are two investigator-initiated randomized controlled trials (RCTs) actively recruiting patients in the unit. The unit has a long experience in patient recruitment for multicenter, industry-initiated RCTs, and currently the unit participates in eight such trials. The hospital is committed to the project.
Prof. Mical Paul (MD) is head of the Unit of Infectious Diseases at Rambam. She is Professor at Sackler Faculty of Medicine Tel-Aviv University and invited Professor at the Technion Israel Institute of Technology; Associate Editor in Chief of Clinical Microbiology and Infection and Editor of the Cochrane Infectious Diseases Group. Mical Paul has over 100 peer-reviewed publications in the field of infectious diseases and antibiotic management, in journals including the BMJ, Annals of Internal Medicine and Clinical Infectious Diseases. Mical Paul participated in the 5th and 6th framework projects